These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 30601083)
1. Characteristics of biological therapy in pediatric patients with Crohn's disease. Tarnok A; Kiss Z; Kadenczki O; Veres G Expert Opin Biol Ther; 2019 Mar; 19(3):181-196. PubMed ID: 30601083 [TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients. Aliyev ER; Hay JW; Hwang C Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265 [TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist. Holko P; Kawalec P; Pilc A Pharmacoeconomics; 2018 Jul; 36(7):853-865. PubMed ID: 29667146 [TBL] [Abstract][Full Text] [Related]
4. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387 [TBL] [Abstract][Full Text] [Related]
5. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Ko Y; Paramsothy S; Yau Y; Leong RW Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447 [TBL] [Abstract][Full Text] [Related]
6. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. Singh S; Fumery M; Sandborn WJ; Murad MH Aliment Pharmacol Ther; 2018 Aug; 48(4):394-409. PubMed ID: 29920733 [TBL] [Abstract][Full Text] [Related]
7. Biological Agents in the Treatment of Crohn's Disease: A Propensity Score-Matched Analysis From the Prospective Persistence Australian National IBD Cohort (PANIC3) Study. Chetwood JD; Ko Y; Pudipeddi A; Kariyawasam V; Paramsothy S; Leong RW Am J Gastroenterol; 2024 Aug; 119(8):1536-1544. PubMed ID: 38275272 [TBL] [Abstract][Full Text] [Related]
9. Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease. Gisbert JP; Chaparro M Drugs; 2023 Sep; 83(13):1179-1205. PubMed ID: 37505446 [TBL] [Abstract][Full Text] [Related]
10. The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era. Vasudevan A; Ip F; Liew D; van Langenberg DR Inflamm Bowel Dis; 2020 Feb; 26(3):369-379. PubMed ID: 31532479 [TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease. Townsend T; Razanskaite V; Dodd S; Storey D; Michail S; Morgan J; Davies M; Penman D; Watters C; Swaminathan M; Sabine J; Chapman A; Smith PJ; Flanagan PK; Reilly I; Bodger K; Subramanian S Aliment Pharmacol Ther; 2020 Oct; 52(8):1341-1352. PubMed ID: 32955122 [TBL] [Abstract][Full Text] [Related]
13. Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature. Olbjørn C; Rove JB; Jahnsen J Paediatr Drugs; 2020 Aug; 22(4):409-416. PubMed ID: 32378002 [TBL] [Abstract][Full Text] [Related]
14. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients. Kawalec P; Moćko P J Comp Eff Res; 2018 Feb; 7(2):101-111. PubMed ID: 29115855 [TBL] [Abstract][Full Text] [Related]
17. Treatment sequence network meta-analysis in Crohn's disease: a methodological case study. Varu A; Wilson FR; Dyrda P; Hazel M; Hutton B; Cameron C Curr Med Res Opin; 2019 May; 35(5):733-756. PubMed ID: 30727745 [TBL] [Abstract][Full Text] [Related]
18. Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach. Peyrin-Biroulet L; Danese S; Cummings F; Atreya R; Greveson K; Pieper B; Kang T Expert Rev Gastroenterol Hepatol; 2019 Aug; 13(8):731-738. PubMed ID: 31322440 [No Abstract] [Full Text] [Related]
19. [Vedolizumab in the treatment of Crohn's disease]. Gisbert JP; Domènech E Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903 [TBL] [Abstract][Full Text] [Related]